这就是为什么EuropeanFederationofPharmaceuticalIndustriesandAssociations(EFPIA) commissionedthepresentImpactAssessment,whichaimstocomplementtheevidencebasesupportingproposedpolicyrevisionsdevelopedbyTechnopolis.Thisassessmentwasconductedindependent,withEFPIAMembers 仅限于验证假设基于他们的专业知识。 这项研究依赖于风险调整净现值...
EFPIA’s “Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organizations,” agreed to in July 2013, requires its members to disclose any direct payments or other forms of support made to healthcare professionals.This information will...
n by Members of the European Parliament to not link regulatory data protection(RDP)to medicine availability.Finding workable solutions to improve patient access to medicines will require multi-stakeholder collaboration and consideration of the multifactorial nature of root causes of unavailability a 17、...
The founding industry members (European Federation of Pharmaceutical Industries and Associations [EFPIA], Japanese Pharmaceutical Manufacturers Association... Hironobu,Saito,Masafumi,... - 《Therapeutic Innovation & Regulatory Science》 被引量: 0发表: 2017年 The Evolution of Medical Affairs A case study...
The consolidated Code was broadened to include a new section on medical education that outlines the scope of member companies' engagement in "medical education activities?. This new section is controversial as it explicitly confirms that EFPIA members can be involved in medical education. In our ...
including the use of external The root causes of unavailability of innovative medicines and delays in access June 2024 Page 40 reference pricing and extraterritoriality.EFPIA members support an EBTP approach based on a concrete conceptual framework101 with the following characteristicsTo promote faster ...